AACR-AstraZeneca/MedImmune Clinical Immuno-oncology Research Training Fellowships

2018 Program Guidelines and Application Instructions
TABLE OF CONTENTS

PROGRAM SUMMARY ........................................................................................................................3
APPLICATION DEADLINE ..................................................................................................................3
APPLICANT ELIGIBILITY CRITERIA ...............................................................................................3
RESEARCH YEAR AT ASTRAZENECA ...........................................................................................4
LETTERS OF REFERENCE ............................................................................................................4
EVALUATION OF APPLICATIONS ...............................................................................................5
TOBACCO INDUSTRY FUNDING AND CONFLICTS OF INTEREST STATEMENT ......................5
APPLICATION PROCEDURES ........................................................................................................6
GETTING STARTED IN proposalCENTRAL .................................................................................6
APPLICATION FORMAT ...............................................................................................................7
SUBMITTING COMPLETE APPLICATION ..................................................................................12
CHANGES TO YOUR APPLICATION ............................................................................................13
INQUIRIES .....................................................................................................................................13
MORE ABOUT THE PARTNERS ....................................................................................................14
PROGRAM GUIDELINES

PROGRAM SUMMARY
Physician-scientists often receive world-class training in patient care, including the newest technologies and approaches to diagnose and treat disease. However, these clinicians also require additional training in laboratory and clinic-based research, in order to stay up-to-date with the pace of medical progress. As such, many fellowship programs offer a “research” year to these young physician-scientists to ensure they have sufficient expertise to contribute to laboratory-based research projects or clinical trials that will advance medical practice and improve patient outcomes.

Many of these training experiences occur in an academic setting, and are focused mainly on retrospective clinical trials, or basic, laboratory-based science; there is a paucity of training opportunities for clinical fellows to gain expertise in conducting an early-stage or a late-stage clinical trial. The AACR-AstraZeneca/MedImmune Clinical Immuno-oncology Research Training Fellowships Program is designed to fill this knowledge gap by providing physician-scientists with real-world experience in early-stage or late-stage clinical development at the facilities of AstraZeneca and its Affiliates.

Each fellowship provides $100,000 over one year to support the salary and benefits of the fellow while working on a mentored research project at one of facilities of AstraZeneca and its Affiliates. Outstanding fellows may be invited to extend the fellowship for an additional year.

It is anticipated that two fellowships will be funded, one for early-stage research and one for late-stage clinical development in immuno-oncology research.

APPLICATION DEADLINE
May 4, 2018 at 1:00 p.m. U.S. Eastern Time

NOTIFICATION OF AWARD
June 2018

ANNUAL GRANTS RECEPTION AND DINNER AT AACR ANNUAL MEETING 2019
April 2, 2019 – Grant recipient must attend the Grants Reception and Dinner to formally accept the grant. Grant funds may be used to support the grantees’ registration and attendance at this Annual Meeting.

START OF GRANT TERM
July 1, 2018

APPLICANT ELIGIBILITY CRITERIA
Applicants must have a medical degree (including MD, DO, or MD/PhD) in a related field, and not currently be a candidate for a further doctoral degree. Additionally, at the start of the grant term, eligible applicants must be enrolled in an accredited hematology/oncology fellowship program at an
academic, medical, or research institution within the United States. *(There are no citizenship requirements. However, by submitting an application for this grant, the applicant who is not a U.S. citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term.)*

Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible.

AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Associate Membership by *Friday, May 4, 2018*. Nonmembers can apply for membership using the [Official Application for Membership](#) submitted to the AACR with the required documents or apply online. In support of the professional development of early-career investigators, no annual dues are required for Associate membership.

Investigators may submit only one application for the AACR-AstraZeneca/MedImmune Clinical Immuno-oncology Research Training Fellowships but may concurrently apply for other AACR grants. However, applicants are expected to accept the first grant they are awarded. Individuals may accept and hold only one AACR grant at a time.

*Any individual who currently holds an active AACR grant may not apply.* Past grantees may apply if they complied with all progress and financial report requirements.

All applicants with questions about eligibility must contact AACR’s SRGA before submitting an application.

**RESEARCH YEAR AT ASTRAZENECA**

During the research year at one of the facilities of AstraZeneca or one of its Affiliates, the fellows will be paired with an AstraZeneca scientist who will serve as their mentor. Research conducted during this year will provide the fellow with the opportunity to gain experience in drug development and understand challenges in early-stage and late-stage immuno-oncology (IO). The fellows will learn the fundamentals of conducting early-phase or late-phase clinical research in IO, such as understanding potential predictors of response to IO therapies, identifying early response endpoints, and developing optimal trial design methods for evaluating a large number of novel IO-IO and IO-Standard of Care combinations and quickly identifying the most promising combinations. They will also learn about trial design, data analysis, and protocol development during their fellowship. The fellows will be accountable for executing clinical research in IO and completing the research within the one-year program. Outstanding fellows may be invited to extend the fellowship for an additional year. Opportunities for publication and presentation of the research will be provided, including participation in the annual AstraZeneca Scientific Forum for Fellows.

**LETTERS OF REFERENCE**

Each applicant must have a letter of reference from their academic mentor accompany the online application. If the academic mentor is not an active, emeritus, or honorary member of AACR, an additional letter of reference from an endorser who is an active, emeritus, or honorary member of AACR must accompany the application. If an applicant’s academic mentor is an AACR member, a letter of reference from an endorser will not be accepted. Instructions for submitting letter(s) of reference are addressed in Section 6 of the Application Instructions.

*NOTE: Significant weight will be given to this letter in the evaluation of the application, as it should*
detail the applicant’s scientific and clinical merit, as well as their potential to become a leader in the field. Letters should only be provided by the academic mentor; the AstraZeneca-appointed mentor will be provided at the time of award.

EVALUATION OF APPLICATIONS
Applications will be peer-reviewed by a Scientific Review Committee comprised of scientists from both AACR and AstraZeneca who are well-respected for their own accomplishments in oncology research and are viewed as leaders in the field. The President of the AACR, in collaboration with AACR’s CEO, MedImmune’s Vice President & Head of Clinical Development for Oncology, and AstraZeneca’s Head of Cancer Immunotherapy in Global Medicines Development, will appoint the members of the Scientific Review Committee. The Committee will consider the following criteria when reviewing applications and determining funding decisions:

- **Applicant**: What training and experience does the applicant have to ensure successful implementation of the proposed project? Is their academic record and research experience of high quality? Does the applicant have the potential to develop as an independent and productive researcher in the field? Is the applicant motivated and enthusiastic about the IO field? Will the development of the applicant’s career benefit from the program? How does the applicant plan to apply their training to their future work as a physician-scientist?

- **Training Environment**: Is there appropriate commitment from both the institution and AstraZeneca to foster the applicant’s training to become a productive researcher in the field?

TOBACCO INDUSTRY FUNDING AND CONFLICTS OF INTEREST STATEMENT
A Fellow whose named mentor is funded by the tobacco industry for any research project is not eligible for any AACR grant. A Grantee or their named mentor who accepts funding from the tobacco industry for any research project during the term of an AACR grant must inform AACR of such funding, whereupon the AACR grant will be immediately terminated.

Tobacco industry funding is defined for the purposes of AACR grant applicants and recipients as money provided or used for all or any of the costs of any research project, including personnel, consumables, equipment, buildings, travel, meetings and conferences, and operating costs for laboratories and offices. It is not defined as money provided or used for meetings or conferences that do not relate to any particular research project.

Tobacco industry funding includes: funds from a company that is engaged in or has affiliates engaged in the manufacture of tobacco produced for human use; funds in the name of a tobacco brand, whether or not the brand name is used solely for tobacco products; funds from a body set up by the tobacco industry or by one or more companies engaged in the manufacture of tobacco products.

The following do not constitute tobacco industry funding for the purposes of this policy:
- Legacies from tobacco industry investments (unless the names of a tobacco company or cigarette brand are associated with them)
- Funding from a trust or foundation established with assets related to the tobacco industry but no longer having any connection with the tobacco industry even though it may bear a name that (for historical reasons) is associated with the tobacco industry.
APPLICATION INSTRUCTIONS

APPLICATION PROCEDURES
AACR requires applicants to submit an online application by 1:00 p.m. U.S. Eastern Time on Friday, May 4, 2018, using the proposalCENTRAL website at https://proposalcentral.altum.com.

In order to submit a complete application, applicants need to enter information directly into the online application platform as well as upload a number of documents. The following instructions provide details about information that needs to be entered and the materials that need to be uploaded. The section numbering corresponds with the section number of the Application Instructions and the online proposalCENTRAL application.

<table>
<thead>
<tr>
<th>Information to be Entered Directly into proposalCENTRAL</th>
<th>Application Instructions Section</th>
<th>proposalCENTRAL Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Name</td>
<td>1. Applicant Name</td>
<td>1) Applicant Name</td>
</tr>
<tr>
<td>Applicant Additional Information</td>
<td>2. Applicant Additional Information</td>
<td>2) Applicant Additional Information</td>
</tr>
<tr>
<td>Institution and Contact Information</td>
<td>4. Institution &amp; Contacts</td>
<td>4) Institution &amp; Contacts</td>
</tr>
<tr>
<td>Budget</td>
<td>7. Budget</td>
<td>7) Budget</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Templates</th>
<th>Application Instructions Section</th>
<th>proposalCENTRAL Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Career Development Statement</td>
<td>8.A. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Secured Other Support Template</td>
<td>8.B. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Pending Other Support Template</td>
<td>8.C. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Budget Justification Template</td>
<td>8.D. Application Documents</td>
<td>8) Application Documents</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Materials</th>
<th>Application Instructions Section</th>
<th>proposalCENTRAL Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter(s) of Reference (uploaded by Mentor and Endorser [if necessary])</td>
<td>6. Letters of Reference</td>
<td>6) Letters of Reference</td>
</tr>
<tr>
<td>Applicant’s Curriculum Vitae</td>
<td>8.E. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Mentor’s Biographical Sketch</td>
<td>8.F. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Supporting Documentation (if applicable)</td>
<td>8.G. Application Documents</td>
<td>8) Application Documents</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Required Signatures</th>
<th>Application Instructions Section</th>
<th>proposalCENTRAL Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Agreement Signature Page</td>
<td>8.H. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Intellectual Property Statement</td>
<td>8.I. Application Documents</td>
<td>8) Application Documents</td>
</tr>
<tr>
<td>Application Signature Page</td>
<td>8.J. Application Documents</td>
<td>12) Signature Page(s)</td>
</tr>
</tbody>
</table>

GETTING STARTED IN proposalCENTRAL
If you are a new user of proposalCENTRAL, click the orange “CREATE ONE NOW!” button and complete the registration process. After logging in, complete your Professional Profile (green tab, second from the left) before starting an application.

If you are already registered with proposalCENTRAL, access the site and log in with your Username and Password. If you have forgotten your login information, click on the “Forgot Your Username/Password?”
To start an application, select the “Grant Opportunities” tab (gray tab, furthest to the right). A list of applications will be displayed. The list of applications can be filtered for just this organization by selecting “American Association for Cancer Research” in the drop down menu at the top and clicking “Filter by Grant Maker.” Find the “AACR-AstraZeneca/MedImmune Clinical Immuno-oncology Research Training Fellowships” and click the “Apply Now” link (second to last column) to create your application.

If you have any difficulties registering, logging in, or creating your application, contact proposalCENTRAL Customer Support at 1-800-875-2562, 703-964-5840, or by email at pcsupport@altum.com. See the proposalCENTRAL FAQ section, https://proposalcentral.altum.com/FAQ/FrequentlyAskedQuestions.asp, for additional information.

APPLICATION FORMAT
The following information is required to submit a complete application. Numbers correspond to the application sections found on the left side of the proposalCENTRAL website.

1. **APPLICANT NAME.** Enter applicant name. Applicant name must be entered and saved before additional sections may be accessed.

2. **APPLICANT ADDITIONAL INFORMATION.** Enter information for the applicant. Applicants must include their contact information, including e-mail address, phone number, and mailing address.

3. **ENABLE OTHER USERS TO ACCESS THIS PROPOSAL.** Optional.

4. **INSTITUTION & CONTACTS.** Enter information regarding the applicant’s institution, the mentor, the endorser (if applicable), and signing official.

5. **DOWNLOAD TEMPLATES & INSTRUCTIONS.** The Program Guidelines and Application Instructions document, the Grant Agreement document, and all templates can be downloaded from this page. See Section 8 of the Application Instructions for how to complete and upload the templates. This application also requires additional attachments for which templates are not provided (applicant’s curriculum vitae, mentor’s biographical sketch, and supporting documentation [if applicable]).

6. **LETTERS OF REFERENCE.** Enter the e-mail address of the mentor submitting a letter of reference. Enter the e-mail address again to confirm and click “Add.” If the academic mentor’s e-mail address is in the proposalCENTRAL system, you will be prompted to “Send E-mail” to the mentor. The e-mail will contain instructions and a link to upload the letter of reference directly to the application. If the academic mentor’s e-mail address is not in the proposalCENTRAL system, you will be prompted for the mentor’s first and last name before being prompted to “Send E-mail.”

   If the academic mentor is not an active, emeritus, or honorary member of AACR, repeat the steps above to send a letter of reference request to an endorser who is an active, emeritus, or honorary member of AACR. If your academic mentor is an AACR member, an additional letter of reference from an endorser will not be accepted.

   **Note:** The Letter of Reference is only required from the academic mentor. The AstraZeneca mentor
will be appointed at the time of the award.

The letter(s) of reference are uploaded directly from the academic mentor and endorser (if necessary) to the proposalCENTRAL application. Applications cannot be submitted without a Letter of Reference. Applicants can view letter submission status by returning to Section 6 of the online application.

7. **BUDGET.** Enter expenses for the term of the grant. Applicants must submit a budget in the amount of $100,000. The applicant must dedicate 100% effort to the proposed project for the one year-term spent on site at the AstraZeneca or an Affiliate facility.

The grantee must attend the AACR Annual Meeting 2019 to formally accept the grant during the annual Grants Reception and Dinner. Up to $2,000 may be allocated from the grant to support the grantee’s registration and attendance at this Annual Meeting. No other travel is permitted.

AstraZeneca will provide a limited stipend to allow the fellow to travel to the AstraZeneca site prior to the start of the one-year term to secure accommodations. This stipend will also cover necessary costs for the fellow to travel to and from the AstraZeneca site for the one-year term. Total amount of the stipend will be determined on a case-by-case basis, and will be dependent upon the distance traveled by the fellow, but will be limited to a certain amount. Housing costs during the one-year term are the responsibility of the fellow.

Salary and benefit expenses for any individuals other than the grantee, indirect costs, tuition, travel (other than to the AACR Annual Meeting 2019 noted above), professional membership dues, and any other research expenses are not allowable expenses. For the purposes of this grant, any general office supplies or individual institutional administrative charges (e.g., telephone, other electronic communication, utilities, IT network, etc.) are considered to be part of indirect and are not allowable budget line items. In addition, no grant funds may be directed towards salary or benefits of any individuals from a U.S. government entity or for-profit industry, nor for any research expenses related to the project that are incurred by these individuals.

A detailed budget justification explaining the allocation of the grant funds must accompany the application. See Section 8.D. for Budget Justification template instructions.

8. **APPLICATION DOCUMENTS.**

*Formatting Instructions.* Applicants must adhere to the following instructions in completing the templates. Failure to observe type size specifications and page limits will result in the return of the application without review.

- **Type size.** Must use 12-point Times New Roman for the text, and no smaller than 9-point type for figures, legends, and tables.
- **Single-spaced text.** Single-spacing is acceptable, and space between paragraphs is recommended.
- **Margins.** The page margins must be no less than 0.75 inches on the top, bottom, and both sides.
- **Tips and techniques for inserting images in documents.**
  - Reduce the file size of documents with images by “inserting” the image (as opposed to “cutting” and “pasting”). Save graphical images as a JPG or GIF file. Insert the image into the
document by selecting “Insert – Picture – From File” from the MS Word menu.
  - Insert only GIF or JPG graphic files as images in your Word document. Other graphical file formats are either very large or difficult to manipulate in the document.
  - Do not insert Quick Time or TIFF objects into your document.
  - Anchor the images that you embed in your document.
  - Once you have anchored the inserted image, you can format text to wrap around the image.
  - Do not edit your images in Word. Use a graphics program.
  - Do not embed your images in tables, text boxes, and other form elements.
  - Do not add annotations over the images in Word. Add annotations to the images in a graphics program.

When a template is provided, the template MUST be used. Prepare and upload the following documents into your application in portable document format (PDF):

A. Applicant Career Development Statement. Applicants are required to use the template available from the proposalCENTRAL website. Limited to two pages. Applicants should comment on their medical and scientific background, as well as their motivation for participating in the Clinical Immuno-oncology Research Training Fellowship Program. Applicants should also state their career goals and measurable objectives, including how the experience at AstraZeneca will enhance their research skills and contribute to their career advancement.

B. Secured Other Support. Applicants are required to use the template available from the proposalCENTRAL website. In the table provided, list all existing support (institutional, federal, etc.) that has been secured and will be active during the term of this grant (07/01/2018 – 06/30/2019). Only funding sources that provide support specifically for the applicant should be listed, which includes grants for which the applicant is not the Principal Investigator. This may include support for different projects. For each grant or funding source, please provide:
  - Name of Principal Investigator
  - Name of Grant/Funding Source
  - Funding Agency
  - Grant Term
  - Amount of Funding
  - Percent Effort of Applicant
  - Title of Project
  - List of Specific Aims as Stated in Grant Proposal (summaries will NOT be accepted)

C. Pending Other Support. Applicants are required to use the template available from the proposalCENTRAL website. In the table provided, list all pending support (institutional, federal, etc.) that will, if secured, be used in whole or in part by the applicant during the term of this grant (07/01/2018 – 06/30/2019). Only funding sources that will provide support specifically for the applicant should be listed, which includes grants for which the applicant is not the Principal Investigator. This may include support for different projects. For each pending grant or funding source, please provide:
  - Name of Principal Investigator
  - Name of Grant/Funding Source
• Funding Agency
• Grant Term
• Amount of Funding
• Percent Effort of Applicant
• Title of Project
• List of Specific Aims as Stated in Grant Proposal (summaries will NOT be accepted)

NOTE: If at any time prior to selection and notification an applicant is awarded research funding in addition to the 2018 AACR-AstraZeneca/MedImmune Clinical Immuno-oncology Research Training Fellowship, the applicant must notify AACR immediately. If selected, grant recipients will not be permitted to hold additional funding beyond the AACR-AstraZeneca Fellowship while their grant is active.

D. Budget Justification. Applicants are required to use the template available from the proposalCENTRAL website. Limited to one page. Applicants must submit a budget in the amount of $100,000. Applicants must dedicate 100% effort to the proposed project for the one year-term spent on site at AstraZeneca. Travel expenditures cannot exceed $2,000 for travel to the AACR Annual Meeting 2019 ONLY. Travel funds are for the grantee ONLY.

E. Applicant’s Curriculum Vitae (CV). The CV must be in English and include a complete list of publications.

Note: The NIH Biographical Sketch Format Page will not be accepted from the applicant.

F. Academic Mentor’s Biographical Sketch. The biographical sketch must be in English. Only the NIH Biographical Sketch Form [OMB No. 0925-0001/0002 (Rev. 09/2017)] is acceptable.

G. Supporting Documentation. An example of acceptable supporting documentation is a recently published manuscript or other information that supports the scientific or clinical merit of the applicant. Applicants may provide no more than three supporting documents. Please note that any supporting documents deemed to be additional letters of reference will NOT be accepted. Such documents will be removed from the application prior to review.

H. Grant Agreement Document. In order to ensure that the applicant is informed of the terms and conditions of the grant should they be selected as a recipient, a copy of the Grant Agreement must be downloaded from the proposalCENTRAL site. Applicants must remove the final page of the Grant Agreement document and sign and date it, indicating that they have reviewed the document. Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures.

The terms and conditions of this grant may be modified or amended by AACR prior to execution of the Grant Agreement. In addition, the grant recipient’s institution may only request revisions to the sections VII.E., IX. (which will be negotiated with AstraZeneca), X., XI.E., and XII.A. of the Grant Agreement prior to execution. Only in special circumstances will revisions be considered to sections other than those noted above.
The **signed Grant Agreement final page** must be uploaded to your online application in the Application Documents section.

I. **Intellectual Property Statement.** In order to ensure that the applicant is informed of the intellectual property terms of the grant should they be selected as a recipient, a copy of the Intellectual Property Statement must be downloaded from the proposalCENTRAL site. Applicants must sign and date the statement, indicating that they are aware of the requirement of executing a timely Research Agreement between the Institution and AstraZeneca before confirmation of the grant should they be selected. Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures.

AACR will facilitate contact between the Institution and AstraZeneca so they may directly conduct negotiations regarding the terms and conditions of the Research Agreement. Institution will use good faith efforts to expedite negotiation and execution of the Research Agreement to enable timely confirmation of the grant and commencement of the fellowship.

The **signed Intellectual Property Statement** must be uploaded to your online application in the Application Documents section.

J. **Signed Signature Page.** In order to ensure that the applicant, mentor, and institution have approved the application, applicants must obtain all required signatures on page 1 of the Signature Pages. Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures.

The **signed Signature Page** (with signatures from the applicant, academic mentor, and institution’s signing official) must be uploaded to your online application in the Application Documents section.

**Uploading the attachments into your application.** Once you have converted your attachments to PDF files, the next step is to upload the files to your online application. **Only PDF attachments are permitted for this application submission.**

- Open your online application and go to the section for attaching files.
- Enter your own description of the file in the “Describe Attachment” field.
- Select the appropriate type of attachment from the drop-down list.
- Click on the “Browse” button to select the file from your computer.
- Click on the “Upload Attachment” button. You will get a confirmation message on your screen that the file was uploaded successfully. You will also see that your file is now listed in the “Uploaded Attachment” section of the screen. Two links are available in each row of an uploaded attachment: DEL and SHOW. “DEL” allows you to delete the file, if necessary, and “SHOW” opens the uploaded file. **Open and review your uploaded file.**

In the section for attachments, all the required attachments are listed in the middle of the screen, just below where you upload your files. This list of required attachments helps you track completion and uploading of your required attachments. Once you upload a required attachment, that attachment type will be removed from the required list and will be displayed in the “Current list of uploaded attachments.”
If you wish to modify the attached file, make the revisions to your original file on your computer, convert the file to PDF, and use the same process above to attach the new file. Delete any previously submitted versions of the file before submitting your application.

SUBMITTING COMPLETE APPLICATION
9. PI DATA SHEET. This is an automatically populated data sheet based on the applicants’ proposalCENTRAL profile. Information for gender, race, and ethnicity must be provided to AACR. If fields are not populated, go to Section 2, “Applicant Additional Information”, and select the “Edit Professional Profile” tab in the center of the screen. The applicant must then go to the column on the left side of the screen, select “4) Personal Data for Application,” and enter their gender, race, and ethnicity. The Scientific Review Committee does not receive this information.

10. PI DATA ADDITIONAL INFORMATION. From the lists provided, select the research areas of interest most appropriate to career development (select no more than two), and indicate how you found out about this grant opportunity.

11. VALIDATE. Validate the application on proposalCENTRAL. This is an essential step. An application that has not been validated cannot be submitted. “Validate” checks for required data and attachments. You will not be able to submit if all the required data and attachments have not been provided.

12. SIGNATURE PAGE(S). Use the “Print Signature Pages” button to download the Signature Pages. Signatures are only required on the first page. This page can be printed, original signatures obtained, and then uploaded to your online application. Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures. Do not upload the Application Contacts and Budget pages with the signed Signature Page.

Note: Data entered in the online application are automatically included in the Signature Pages. If information is missing in the Signature Pages, it could be because you have not entered the information in one of the online application sections OR the information is not required for this grant program. If the institution’s Employer Identification Number (EIN) is not completed on the first Signature Page, please request your institution to provide that information in their proposalCENTRAL profile.

While the “Print Signature Pages” option allows applicants to download the Signature Page, Application Contacts, and Budget, the AACR strongly encourages applicants to also utilize the “Print Signature Pages and Attached PDF Files” option. This option can be used if your institution wishes to review the full application but also should be utilized by the applicant to ensure that the Scientific Abstract does not cut-off in this view and that your attachments loaded properly. The following application materials will not be present when utilizing this option: Pending Other Support, Letter(s) of Reference, Grant Agreement Signature Page, Intellectual Property Statement Signature Page, and the Signature Page containing the required signatures. Absence of these materials should not be considered an error. If your institution requires all components of the application to review, the above documents need to be printed individually by the applicant and added; however, as the
Letter(s) of Reference are uploaded directly from the mentor and endorser (if necessary), the applicant will be unable to access these letters.

Errors may occur when the uploaded PDF files are assembled by the system. Please check to ensure that all pages of every document included appear in the “Print Signature Pages and Attached PDF Files” option. If you are having any issues with this option, please contact proposalCENTRAL customer support at 703-964-5840, or toll free at 1-800-875-2562, or by e-mail to pcsupport@altum.com.

AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Associate membership by Friday, May 4, 2018. Nonmembers can apply for membership using the Official Application for Membership submitted to the AACR with the required documents or apply online. In support of the professional development of early-career investigators, no annual dues are required for Associate membership.

13. SUBMIT. After successfully passing the validate check, click the “Submit” link. An e-mail will be sent to you confirming your submission.

Once your application is submitted you may view it by accessing the ‘Submitted’ link under the ‘Manage Proposals’ tab. The status column will show “Submitted” and the date submitted. You may need to refresh your browser screen after submitting the application to see the updated status.

CHANGES TO YOUR APPLICATION
Withdrawal of Application. Please advise AACR promptly, in writing, should you decide to withdraw your application for any reason. Your correspondence must include your name, the grant opportunity to which you applied, the project title, and the reason for withdrawal.

Change of Address. Notify AACR in writing of any changes of address, e-mail, or phone number, following the submission of an application. Include your name and the application number. The e-mail address provided with your application will be utilized for all official communication about your submission including the recipient selection results; your Professional Profile in proposalCENTRAL must be kept up to date.

Change of Institution or Position. If you change your institution or professional position, contact AACR’s SRGA to determine whether your application is still eligible for review.

INQUIRIES
Inquiries or technical issues regarding proposalCENTRAL and the online application process should be directed to customer support at: 703-964-5840, or toll free at 1-800-875-2562, or by e-mail to pcsupport@altum.com.

Inquiries about the program guidelines, eligibility requirements, and application materials can be directed to grants@aacr.org, or by phone at: 215-446-7280 or 215-309-4359.
MORE ABOUT THE PARTNERS

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory, Cardiovascular & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, MD, one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK, and Mountain View, CA. For more information, please visit http://www.medimmune.com.

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in hematology. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR has 40,000 members in 120 countries and territories around the world; over 30 percent of members live outside the United States and Canada. Twenty percent (20%) of AACR’s international members are located in countries with emerging economies. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.